Powered by: Motilal Oswal

News

Tatva Chintan Pharma Chem rises on starting commercial production of new facility at Dahej Manufacturing Plant Tatva Chintan Pharma Chem is currently trading at Rs. 1688.00, up by 9.85 points or 0.59% from its previous closing of Rs. 1678.15 on the BSE. The scrip opened at Rs. 1717.95 and has touched a high and low of Rs. 1728.00 and Rs. 1685.00 respectively. So far 865 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 2649.10 on 22-Sep-2022 and a 52 week low of Rs. 1606.00 on 29-Mar-2023. Last one week high and low of th...
Tatva Chintan Pharma Chem rises on starting commercial production of new facility at Dahej Manufacturing Plant
Tatva Chintan Pharma Chem rises on starting commercial production of new facility at Dahej Manufacturing Plant
Source: Accord Fintech
6/04/2023 3:14:27 PM
Planned CapEx of INR 16,100+ crores from Indian Specialty Chemicals over the next 3 years: Windmill Capital  In a recent study on Specialty Chemicals by Windmill Capital, a wholly- owned subsidiary of smallcase, it is expected that Indian Specialty Chemicals companies have CapEx plans in excess of Rs 16,100 crores over the next 3 years. Asian Paints, Tatva Chintan Pharma, and PI Industries are some companies within the Specialty Chemical sector witnessing margin pressure on the bottom line. The segment is expected to grow 19% in FY24 and 17.6% in FY25. The Specialty Chemic...
Planned CapEx of INR 16,100+ crores from Indian Specialty Chemicals over the next 3 years: Windmill Capital
Planned CapEx of INR 16,100+ crores from Indian Specialty Chemicals over the next 3 years: Windmill Capital
Source: PR Agency
22/03/2023 1:59:30 PM
Buy Tatva Chintan Pharma Chem Ltd For Target Rs.2,860 - ICICI Securities Rising visibility on FY24E EPS growth Tatva Chintan’s Q2FY23 revenue fell 27.1% YoY and EBITDA plunged 68.9% YoY due to lower SDA sales, which seems very disappointing, but we believe this situation is transitory. Company expects recovery in SDA sales in Q4FY23 with revival in heavyduty truck sales in China. Non-SDA business revenue growth was strong, and gross profit margin has been impressive. FY24E outlook is significantly improving on the back of: 1) commercialisation of flame re...
Buy Tatva Chintan Pharma Chem Ltd For Target Rs.2,860 - ICICI Securities
Buy Tatva Chintan Pharma Chem Ltd For Target Rs.2,860 - ICICI Securities
Source: ICICI Securities Ltd
8/11/2022 11:04:14 AM
Buy Tatva Chintan Pharma Chem Ltd For Target Rs.2,730 - ICICI Securities Non-SDA revenue zooms, SDA crashes Tatva Chintan’s Q1FY23 revenue declined 17% YoY and EBITDA dropped 41% YoY, which seem very disappointing. But we believe many stories are concealed behind the numbers and note that the entire under-performance was due to the 89% crash in SDA revenue. However, non-SDA revenue (up 65% YoY, 37% QoQ) was the silver lining, which indeed is heartening. SDA revenue decline is transitory and should grow in parallel with CV demand growth in China and India,...
Buy Tatva Chintan Pharma Chem Ltd For Target Rs.2,730 - ICICI Securities
Buy Tatva Chintan Pharma Chem Ltd For Target Rs.2,730 - ICICI Securities
Source: ICICI Securities Ltd
6/09/2022 10:13:11 AM
Buy Tatva Chintan Pharma Chem Ltd For Target Rs.3,000 - ICICI Securities   Durable growth in niche chemistries We hosted promoters of Tatva Chinta Pharma Chem – Mr. Chintan Shah and Mr. Shekhar Somani for investors meeting. The management expects growth in SDAs to continue, and opportunities are increasing for emission control beyond transport vehicles. Tatva Chintan should grow faster from new customer wins, and likely supply to developed market for Euro-7. It has cracked products that are high in purity, and has found application in semi-conduct...
Buy Tatva Chintan Pharma Chem Ltd For Target Rs.3,000 - ICICI Securities
Buy Tatva Chintan Pharma Chem Ltd For Target Rs.3,000 - ICICI Securities
Source: ICICI Securities Ltd
14/04/2022 11:52:40 AM
Buy Tatva Chintan Pharma Chem Ltd For Target Rs.3,110 - ICICI Securities On track for new initiatives Tatva Chintan’s Q3FY22 revenue growth was 12% lower than our estimate on higher dip in SDA revenue. However, margin expansion of 130bps QoQ despite inferior revenue mix was a positive surprise on better product mix in PTC and PASC. It sees moderate growth even in Q4FY22, but it is building inventory to service higher demand on normalisation. It has acquired two new large customers in SDA which should help accelerate volume off-take and only one large cust...
Buy Tatva Chintan Pharma Chem Ltd For Target Rs.3,110 - ICICI Securities
Buy Tatva Chintan Pharma Chem Ltd For Target Rs.3,110 - ICICI Securities
Source: ICICI Securities Ltd
21/01/2022 10:30:01 AM
Tatva Chintan Pharma Chem trades jubilantly on reporting 9-fold jump in Q2 consolidated net profit Tatva Chintan Pharma Chem is currently trading at Rs. 2316.40, up by 184.35 points or 8.65% from its previous closing of Rs. 2132.05 on the BSE. The scrip opened at Rs. 2415.30 and has touched a high and low of Rs. 2488.90 and Rs. 2283.25 respectively. So far 17653 shares were traded on the counter. The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 2,488.90 on 25-Oct-2021 and a 52 week low of Rs. 2000.75 on 11-Aug-2021. Last one week high and low ...
Tatva Chintan Pharma Chem trades jubilantly on reporting 9-fold jump in Q2 consolidated net profit
Tatva Chintan Pharma Chem trades jubilantly on reporting 9-fold jump in Q2 consolidated net profit
Source: Accord Fintech
25/10/2021 10:14:34 AM
Tatva Chintan Pharma Chem Ltd. debuts with 94.99% premium at Rs 2,111.80 Tatva Chintan Pharma Chem Ltd. makes a strong debut on the bourses with scrip got listed at Rs 2,111.80 on the Bombay Stock Exchange, a 94.99 per cent premium to its issue price of Rs 1,083.00. On the National Stock Exchange, the stock was listed at Rs 2,111.85. The company, which raised 0.46 Cr from initial public offering, was subscribed 126.15 times, receiving bids for 5,824.10 lakhs shares against the total issue size of 46.17 lakhs shares. The company, listed under B Group Securities pos...
Tatva Chintan Pharma Chem Ltd. debuts with 94.99% premium at Rs 2,111.80
Tatva Chintan Pharma Chem Ltd. debuts with 94.99% premium at Rs 2,111.80
Source: Accord Fintech
29/07/2021 2:28:15 PM
Listing Note on Tatva Chintan Pharma Chem Ltd by Ms. Sneha Poddar, Motilal Oswal Financial Services Ltd Below is the Listing Note on Tatva Chintan Pharma Chem by Ms. Sneha Poddar, AVP – Research Analyst, Broking & Distribution, Motilal Oswal Financial Services Ltd Tatva Chintan Pharma Chem (TCPCL), one of the leading specialty chemicals manufacturer globally, had a stellar debut on the exchanges today with  95% premium at INR 2112/Share against its issue price of Rs1083/share. it further rallied towards its intraday high of Rs2486, gaining ~130%. ...
Listing Note on Tatva Chintan Pharma Chem Ltd by Ms. Sneha Poddar, Motilal Oswal Financial Services Ltd
Listing Note on Tatva Chintan Pharma Chem Ltd by Ms. Sneha Poddar, Motilal Oswal Financial Services Ltd
Source: Motilal Oswal Financial Services Ltd
29/07/2021 12:01:26 PM
IPO Note - Tatva Chintan Pharma Chem Ltd By Motilal Oswal Tatva Chintan Pharma Chem Ltd (TCPCL) is a specialty chemicals manufacturer, with a diverse portfolio of structure directing agents (SDAs; 40% of revenues), phase transfer catalysts (PTCs; 27%), electrolyte salts (ES; 1%) for super capacitor batteries (SCB) and pharmaceutical/ agrochemical intermediates and other specialty chemicals (PASC; 30%).3 Leading manufacturer of SDA and PTC globally: TCPCL is the largest and the only manufacturer of SDAs (40% of revenue) for Zeolites in India wh...
IPO Note - Tatva Chintan Pharma Chem Ltd By Motilal Oswal
IPO Note - Tatva Chintan Pharma Chem Ltd By Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
16/07/2021 10:55:29 AM
IPO Note - Tatva Chintan Pharma Chem Ltd By Ventura Securities Tatva Chintan Pharma Chem Ltd (TCPCL), established in 1996, is one of the leading companies engaged in the manufacturing of green chemicals such as structure directing agents (SDA), phase transfer catalyst (PTC), electrolyte salts for super capacitor batteries, pharmaceutical & agrochemical intermediates, and other specialty chemicals. For the products SDA, PTC and electrolyte salts, TCPCL is the largest producer in India, while it ranks 2 nd globally for Zeolite. SDA and PTC products hav...
IPO Note - Tatva Chintan Pharma Chem Ltd By Ventura Securities
IPO Note - Tatva Chintan Pharma Chem Ltd By Ventura Securities
Source: Ventura Securities Ltd
16/07/2021 10:46:26 AM
IPO Note - Tatva Chintan Pharma Chem Ltd By Nirmal Bang BACKGROUND Company Overview Incorporated in 1996, Tatva Chintan Pharma Chem Ltd (TCPC) is a specialty chemical manufacturing company engaged in the manufacture of a diverse portfolio of structure directing agents (“SDAs”), phase transfer catalysts (“PTCs”), electrolyte salts for super capacitor batteries and pharmaceutical and agrochemical intermediates and other specialty chemicals (“PASC”). TCPC is the largest and only commercial manufacturer of SDA...
IPO Note - Tatva Chintan Pharma Chem Ltd By Nirmal Bang
IPO Note - Tatva Chintan Pharma Chem Ltd By Nirmal Bang
Source: Nirmal Bang Ltd
16/07/2021 10:11:09 AM
Quote on Tatva Chintan Pharma Receives Sebi by Mr. Yash Gupta, Angel Broking Ltd Below are Quote on Tatva Chintan Pharma Receives Sebi by Mr. Yash Gupta, Equity Research Associate, Angel Broking Ltd  Tatva Chintan Pharma Receives Sebi Nod For ₹ 450 crore IPO Gujarat based Tatva chintan pharma received SEBI approval for the ₹450 crores IPO consisting of fresh issue of ₹225 crores and offer for sale of ₹225 crores by existing shareholders. Company will utilise a fresh issue of ₹225 crores to fund its capex plans like Dahej manufacturing pla...
Quote on Tatva Chintan Pharma Receives Sebi by Mr. Yash Gupta, Angel Broking Ltd
Quote on Tatva Chintan Pharma Receives Sebi by Mr. Yash Gupta, Angel Broking Ltd
Source: Angel Broking Ltd
12/07/2021 3:34:10 PM